Description
Indimitecan (LMP776) is a topoisomerase I ( Top1 ) inhibitor with anticancer activitiesIn VitroIndimitecan (LMP776) (0-100 µM) shows antiproliferative potencies against various human cancer cell lines, with mean-graph midpoint (MGM) of 0.079 ± 0.023 µM. Indimitecan shows potent DNA cleavage due to Top1 inhibition. Indimitecan can be substrates for metabolic ketone reductases. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145, MCF-7 Concentration: 0-100 µM Incubation Time: Result: Showed growth inhibition with GI 50 s of <0.01, <0.01, 0.04, <0.01, 0.08, <0.01, <0.01 and 0.01 µM against HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145 and MCF-7 cells, respectively. And the mean-graph midpoint (MGM) for growth inhibition of all human cancer cell lines successfully tested (the National Cancer Institute’s developmental therapeutics assay (the “NCI60”)) was 0.079 ± 0.023 µM.Form:SolidIC50& Target:Top1